country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-172394

Copy Link Print Information

ZSNI-21

ZSNI-21 is a ADAM17/HDAC2 inhibitor with ADAM17 IC₅₀ 0.939 μM and HDAC2 IC₅₀ 0.844 μM. ZSNI-21 regulates the expression of apoptosis-related proteins (Bax, Bcl-2) and Cyclin D1, and induces apoptosis.. ZSNI-21 can be used for the research of hepatocellular carcinoma, breast cancer, and non-small cell lung cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₂₆H₂₅N₃O₅
Molecular Weight:459.49

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

ZSNI-21 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

HDAC2

0.844 μM (IC₅₀)

HDAC6

0.106 μM (IC₅₀)

HDAC1

1.270 μM (IC₅₀)

Bax

Bcl-2

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

In Vitro

ZSNI-21 (48 h) potently inhibits proliferation of Bel-7402, HCC-LM3, RBE, MCF-7, and A549 cancer cells with IC₅₀ values ranging from 2.399 μM to 5.789 μM, while exhibiting low toxicity to HL-7702 and HEK 293 T normal cells^[1].
ZSNI-21 functions as a dual inhibitor of ADAM17 and HDAC2 with IC₅₀ values of 0.939 μM and 0.844 μM respectively, while also potently inhibiting HDAC6 (IC₅₀ = 0.106 μM) and moderately inhibiting HDAC1 (IC₅₀ = 1.270 μM)^[1].
ZSNI-21 (6 h) exhibits strong intracellular binding affinity for ADAM17, HDAC1, HDAC2, and HDAC6 in Bel-7402 cells^[1].
ZSNI-21 (1.5-12 μM; 48 h) reduces Notch intracellular domain (NICD) levels, increases acetylated histone H3 and H4 levels, modulates apoptosis-related proteins, and decreases Cyclin D1 expression in Bel-7402 cells^[1].
ZSNI-21 (3-12 μM; 24 h) inhibits long-term proliferation and colony formation of Bel-7402 cells in a concentration-dependent manner^[1].
ZSNI-21 (1.5-12 μM; 48 h) induces apoptosis in Bel-7402 cells in a concentration-dependent manner, as evidenced by apoptotic nuclear morphology and increased total apoptosis proportion (up to 40.2%)^[1].
ZSNI-21 (1.5-6 μM; 48 h) inhibits migration of HCC-LM3 cells and reduces expression of EMT-related proteins in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

human hepatocellular carcinoma Bel-7402 cells
Concentration:

1.5 μM; 3 μM; 6 μM; 12 μM
Incubation Time:

48 h
Result:

Significantly reduced NICD levels in a concentration-dependent manner (with stronger inhibition than ADAM17 inhibitor JG26).
Significantly increased levels of acetylated histones H3 and H4 (comparable to HDAC inhibitor SAHA).
Downregulated pro-caspase-3 expression in a concentration-dependent manner.
Downregulated Cyclin D1 expression in a concentration-dependent manner.
Downregulated Bcl-2 expression in a concentration-dependent manner.
Upregulated Bax expression in a concentration-dependent manner.

Cell Proliferation Assay^[1]

Cell Line:

human hepatocellular carcinoma Bel-7402 cells
Concentration:

3 μM; 6 μM; 12 μM
Incubation Time:

24 h
Result:

Significantly reduced colony formation of Bel-7402 cells in a concentration-dependent manner, with colony formation rates decreasing notably at higher concentrations.

Apoptosis Analysis^[1]

Cell Line:

human hepatocellular carcinoma Bel-7402 cells
Concentration:

1.5 μM; 3 μM; 6 μM; 12 μM
Incubation Time:

48 h
Result:

Induced nuclear shrinkage and chromatin condensation (apoptotic features) in treated cells via Hoechst 33342 staining.
Increased total apoptosis proportion from 7% in controls to 15.83% to 40.2% in treated cells in a concentration-dependent manner via Annexin V-FITC/PI flow cytometry.

Cell Migration Assay ^[1]

Cell Line:

human highly invasive hepatocellular carcinoma HCC-LM3 cells
Concentration:

1.5 μM; 3 μM; 6 μM
Incubation Time:

48 h
Result:

Significantly inhibited HCC-LM3 cell migration in a concentration-dependent manner via wound healing scratch assay.
Significantly reduced vimentin expression in a concentration-dependent manner via immunofluorescence and Western blot.
Significantly reduced Slug expression in a concentration-dependent manner via Western blot.
Significantly reduced MMP9 expression in a concentration-dependent manner via Western blot.

In Vivo

ZSNI-21 (2000 mg/kg; i.g.; single dose) demonstrates high in vivo safety at a single 2000 mg/kg intragastric dose in C57BL/6 mice, with no observed mortality, weight loss, or organ pathology over 14 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (female and male)^[1]
Dosage:

2000 mg/kg
Administration:

i.g.; single dose; 14-day observation
Result:

Showed no mortality over the 14-day period.
Showed no significant weight loss over the 14-day period.
Showed no significant pathological changes in heart, liver, spleen, lung, and kidney compared to controls.

Chemical Information

Molecular Weight 459.49
Formel C₂₆H₂₅N₃O₅
SMILES

COC(C=C1)=CC=C1OCCN2C(C)=C(C(NC3=CC=C(C(NO)=O)C=C3)=O)C4=C2C=CC=C4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Song X, et al. Discovery and evaluation of novel Benzohydroxamic acid-indole derivatives as dual inhibitors of ADAM17 and HDAC2 with antitumor activity. Bioorg Chem. 2025;157:108308. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ZSNI-21

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen